FDA considers anemia drug trials on safety concerns

FDA staffers say that there is not enough data to ensure that two blockbuster anemia drugs--Amgen's Aranesp and J&J's Procrit--are safe when taken by patients receiving chemotherapy. And the regulators may ask the companies to conduct new trials to put their drugs to the test. An FDA panel is being tasked to review anemia drugs on Thursday. The agency recently required new safety labels warning patients and physicians about using dosages of the drugs at levels that are higher than recommended.

- read the AP report on the FDA's review

Related Articles:
Regulators question anemia drugs. Report
New study points to danger of anemia drug. Report
Amgen stock slips as anemia drug concerns rise. Report